Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysis

Citations

Cited by:

1. Andrea Manca & Nigel Rice & Mark J. Sculpher & Andrew H. Briggs, 2005. "Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 471-485, May.
2. Noemi Kreif & Richard Grieve & Rosalba Radice & Zia Sadique & Roland Ramsahai & Jasjeet S. Sekhon, 2012. "Methods for Estimating Subgroup Effects in Cost-Effectiveness Analyses That Use Observational Data," Medical Decision Making, , vol. 32(6), pages 750-763, November.
3. Victoria K. Brennan & Georgina Jones & Stephen Radley & Simon Dixon, 2021. "Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 747-756, September.
4. Rissanen, Elisa & Karjalainen, Piia & Kiviruusu, Olli & Kankaanpää, Eila & Aronen, Eeva T. & Haula, Taru & Sääksvuori, Lauri & Vornanen, Riitta & Linnosmaa, Ismo, 2024. "Cost-effectiveness of a parenting program to reduce children’s behavioral problems among families receiving child protection services and other family support services – A randomized controlled trial," Children and Youth Services Review, Elsevier, vol. 158(C).
5. David Meads & Andrea Marshall & Claire Hulme & Janet Dunn & Hugo Ford, 2016. "The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial," PharmacoEconomics, Springer, vol. 34(1), pages 33-42, January.
6. Andrew M. Jones & James Lomas & Nigel Rice, 2015. "Healthcare Cost Regressions: Going Beyond the Mean to Estimate the Full Distribution," Health Economics, John Wiley & Sons, Ltd., vol. 24(9), pages 1192-1212, September.
7. Yong-Jin Kim & Mark Oremus & Helen H. Chen & Thomas McFarlane & Danielle Fearon & Susan Horton, 2021. "Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada," PharmacoEconomics, Springer, vol. 39(5), pages 537-548, May.
8. Jones, A. & Lomas, J. & Rice, N., 2014. "Going Beyond the Mean in Healthcare Cost Regressions: a Comparison of Methods for Estimating the Full Conditional Distribution," Health, Econometrics and Data Group (HEDG) Working Papers 14/26, HEDG, c/o Department of Economics, University of York.
9. Noémi Kreif & Richard Grieve & M. Zia Sadique, 2013. "Statistical Methods For Cost‐Effectiveness Analyses That Use Observational Data: A Critical Appraisal Tool And Review Of Current Practice," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 486-500, April.
10. A. Gafni & S. D. Walter & S. Birch & P. Sendi, 2008. "An opportunity cost approach to sample size calculation in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 17(1), pages 99-107, January.
11. Richard Grieve & Richard Nixon & Simon G. Thompson & Charles Normand, 2005. "Using multilevel models for assessing the variability of multinational resource use and cost data," Health Economics, John Wiley & Sons, Ltd., vol. 14(2), pages 185-196, February.
12. Claudia Schulz & Gisela Büchele & Raphael S. Peter & Dietrich Rothenbacher & Christian Brettschneider & Ulrich C. Liener & Clemens Becker & Kilian Rapp & Hans-Helmut König, 2021. "Health-economic evaluation of collaborative orthogeriatric care for patients with a hip fracture in Germany: a retrospective cohort study using health and long-term care insurance claims data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(6), pages 873-885, August.
13. Gemma E. Shields & Mark Wilberforce & Paul Clarkson & Tracey Farragher & Arpana Verma & Linda M. Davies, 2022. "Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency," PharmacoEconomics, Springer, vol. 40(2), pages 149-156, February.
14. Richard Grieve & John Cairns & Simon G. Thompson, 2010. "Improving costing methods in multicentre economic evaluation: the use of multiple imputation for unit costs," Health Economics, John Wiley & Sons, Ltd., vol. 19(8), pages 939-954, August.
15. Manuel Gomes & Richard Grieve & Richard Nixon & W. J. Edmunds, 2012. "Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials," Medical Decision Making, , vol. 32(1), pages 209-220, January.
16. Andrea Manca & Paul C. Lambert & Mark Sculpher & Nigel Rice, 2007. "Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling," Medical Decision Making, , vol. 27(4), pages 471-490, July.
17. Ilias Goranitis & Joanna Coast & Ed Day & Alex Copello & Nick Freemantle & Emma Frew, 2017. "Maximizing Health or Sufficient Capability in Economic Evaluation? A Methodological Experiment of Treatment for Drug Addiction," Medical Decision Making, , vol. 37(5), pages 498-511, July.
18. Gafni, Amiram & Birch, Stephen, 2006. "Incremental cost-effectiveness ratios (ICERs): The silence of the lambda," Social Science & Medicine, Elsevier, vol. 62(9), pages 2091-2100, May.
19. Manuel Gomes & Richard Grieve & Richard Nixon & Edmond S.‐W. Ng & James Carpenter & Simon G. Thompson, 2012. "Methods For Covariate Adjustment In Cost‐Effectiveness Analysis That Use Cluster Randomised Trials," Health Economics, John Wiley & Sons, Ltd., vol. 21(9), pages 1101-1118, September.
20. Negri­n, Miguel A. & Vázquez-Polo, Francisco-José, 2008. "Incorporating model uncertainty in cost-effectiveness analysis: A Bayesian model averaging approach," Journal of Health Economics, Elsevier, vol. 27(5), pages 1250-1259, September.
21. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
22. Andrew H. Briggs, 2022. "Healing the past, reimagining the present, investing in the future: What should be the role of race as a proxy covariate in health economics informed health care policy?," Health Economics, John Wiley & Sons, Ltd., vol. 31(10), pages 2115-2119, October.
23. Caffray, Christine M. & Chatterji, Pinka, 2009. "Developing an Internet-based survey to collect program cost data," Evaluation and Program Planning, Elsevier, vol. 32(1), pages 62-73, February.
24. Padraig Dixon & William Hollingworth & Jonathan Benger & James Calvert & Melanie Chalder & Anna King & Stephanie MacNeill & Katherine Morton & Emily Sanderson & Sarah Purdy, 2020. "Observational Cost-Effectiveness Analysis Using Routine Data: Admission and Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary Disease," PharmacoEconomics - Open, Springer, vol. 4(4), pages 657-667, December.
25. Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind, 2017. "Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial," PharmacoEconomics - Open, Springer, vol. 1(3), pages 175-184, September.
26. Ya-Chen Shih & Nebiyou Bekele & Ying Xu, 2007. "Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients," PharmacoEconomics, Springer, vol. 25(10), pages 843-862, October.
27. Daisuke Goto & Ya-Chen Tina Shih & Pascal Lecomte & Melvin Olson & Chukwukadibia Udeze & Yujin Park & C. Daniel Mullins, 2017. "Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(7), pages 685-695, July.
28. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
29. Carmen Selva-Sevilla & Elena Conde-Montero & Manuel Gerónimo-Pardo, 2020. "Bayesian Regression Model for a Cost-Utility and Cost-Effectiveness Analysis Comparing Punch Grafting Versus Usual Care for the Treatment of Chronic Wounds," IJERPH, MDPI, vol. 17(11), pages 1-21, May.
30. Francisco-José Polo & Miguel Negrín & Xavier Badía & Montse Roset, 2005. "Bayesian regression models for cost-effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 45-52, March.
31. Lynch, Frances L. & Dickerson, John F. & Saldana, Lisa & Fisher, Phillip A., 2014. "Incremental net benefit of early intervention for preschool-aged children with emotional and behavioral problems in foster care," Children and Youth Services Review, Elsevier, vol. 36(C), pages 213-219.
32. Andrew Briggs, 2012. "Statistical Methods for Cost-effectiveness Analysis Alongside Clinical Trials," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 50, Edward Elgar Publishing.
33. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333, March.
34. Mike Paulden, 2020. "Why it’s Time to Abandon the ICER," PharmacoEconomics, Springer, vol. 38(8), pages 781-784, August.
35. Wang, Limin, 2003. "Determinants of child mortality in LDCs: Empirical findings from demographic and health surveys," Health Policy, Elsevier, vol. 65(3), pages 277-299, September.
36. Canaviri, Jose, 2007. "A Random Parameter Logit model for modeling Health Care Provider Choice in Bolivia," MPRA Paper 3263, University Library of Munich, Germany.
37. DE RIDDER, Annemieke & DE GRAEVE, Diana, 2007. "Comparing the cost-effectiveness of Haloperidol, Risperidone and Olanzapine in the treatment of schizophrenia using the net-benefit regression approach," Working Papers 2007012, University of Antwerp, Faculty of Business and Economics.
38. Jasjeet Singh Sekhon & Richard D. Grieve, 2012. "A matching method for improving covariate balance in cost‐effectiveness analyses," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 695-714, June.
39. Carl Bonander & Mikael Svensson, 2021. "Using causal forests to assess heterogeneity in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 30(8), pages 1818-1832, August.
40. Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore, 2013. "Acknowledging Patient Heterogeneity in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(2), pages 111-123, February.
41. Hoch, Jeffrey S. & Blume, Jeffrey D., 2008. "Measuring and illustrating statistical evidence in a cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(2), pages 476-495, March.
42. Theodoros Mantopoulos & Paul M. Mitchell & Nicky J. Welton & Richard McManus & Lazaros Andronis, 2016. "Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 927-938, November.
43. Andrew M. Jones & James Lomas & Peter T. Moore & Nigel Rice, 2016. "A quasi-Monte-Carlo comparison of parametric and semiparametric regression methods for heavy-tailed and non-normal data: an application to healthcare costs," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 179(4), pages 951-974, October.
44. Katia Noyes & Andrew W. Dick & Robert G. Holloway, 2004. "Pramipexole v. Levodopa as Initial Treatment for Parkinson’s Disease: A Randomized Clinical-Economic Trial," Medical Decision Making, , vol. 24(5), pages 472-485, October.
45. Zou, Guang Yong & Taleban, Julia & Huo, Cindy Y., 2009. "Confidence interval estimation for lognormal data with application to health economics," Computational Statistics & Data Analysis, Elsevier, vol. 53(11), pages 3755-3764, September.
46. John Hutton, 2012. "‘Health Economics’ and the evolution of economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 21(1), pages 13-18, January.
47. William Hollingworth & Christopher G. Fawsitt & Padraig Dixon & Larisa Duffy & Ricardo Araya & Tim J. Peters & Howard Thom & Nicky J. Welton & Nicola Wiles & Glyn Lewis, 2020. "Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT," PharmacoEconomics - Open, Springer, vol. 4(3), pages 427-438, September.
48. Sennen Hounton & David Newlands, 2012. "Applying the Net-Benefit Framework for Analyzing and Presenting Cost-Effectiveness Analysis of a Maternal and Newborn Health Intervention," PLOS ONE, Public Library of Science, vol. 7(7), pages 1-8, July.
49. Hormuzd A. Katki & Ionut Bebu, 2021. "A simple framework to identify optimal cost‐effective risk thresholds for a single screen: Comparison to Decision Curve Analysis," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 184(3), pages 887-903, July.
50. Richard Grieve & Richard Nixon & Simon G. Thompson & John Cairns, 2007. "Multilevel models for estimating incremental net benefits in multinational studies," Health Economics, John Wiley & Sons, Ltd., vol. 16(8), pages 815-826, August.
51. Todd H. Wagner & Alex R. Dopp & Heather T. Gold, 2020. "Estimating Downstream Budget Impacts in Implementation Research," Medical Decision Making, , vol. 40(8), pages 968-977, November.
52. Elamin H. Elbasha, 2005. "Risk aversion and uncertainty in cost‐effectiveness analysis: the expected‐utility, moment‐generating function approach," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 457-470, May.
53. Andrew R. Willan & Andrew H. Briggs & Jeffrey S. Hoch, 2004. "Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness data," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 461-475, May.
54. Christian Brettschneider & Sebastian Kohlmann & Benjamin Gierk & Bernd Löwe & Hans-Helmut König, 2017. "Depression screening with patient-targeted feedback in cardiology: The cost-effectiveness of DEPSCREEN-INFO," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-15, August.
55. Yu-Wen Wen & Yi-Wen Tsai & David Bin-Chia Wu & Pei-Fen Chen, 2013. "The Impact of Outliers on Net-Benefit Regression Model in Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 8(6), pages 1-9, June.
56. Lukasz Tanajewski & Matthew Franklin & Georgios Gkountouras & Vladislav Berdunov & Judi Edmans & Simon Conroy & Lucy E Bradshaw & John R F Gladman & Rachel A Elliott, 2015. "Cost-Effectiveness of a Specialist Geriatric Medical Intervention for Frail Older People Discharged from Acute Medical Units: Economic Evaluation in a Two-Centre Randomised Controlled Trial (AMIGOS)," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-18, May.
57. Jason R. Guertin & Blanchard Conombo & Raphaël Langevin & Frédéric Bergeron & Anne Holbrook & Brittany Humphries & Alexis Matteau & Brian J. Potter & Christel Renoux & Jean-Éric Tarride & Madelein, 2020. "A Systematic Review of Methods Used for Confounding Adjustment in Observational Economic Evaluations in Cardiology Conducted between 2013 and 2017," Medical Decision Making, , vol. 40(5), pages 582-595, July.
58. Andrea Manca & Neil Hawkins & Mark J. Sculpher, 2005. "Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 487-496, May.
59. Mohamed El Alili & Johanna M. van Dongen & Jonas L. Esser & Martijn W. Heymans & Maurits W. van Tulder & Judith E. Bosmans, 2022. "A scoping review of statistical methods for trial‐based economic evaluations: The current state of play," Health Economics, John Wiley & Sons, Ltd., vol. 31(12), pages 2680-2699, December.
60. Alexander Thompson & Bruce Guthrie & Katherine Payne, 2017. "Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention," Medical Decision Making, , vol. 37(7), pages 759-769, October.
61. Anna M. Kashcheeva, 2019. "Assessment of the factors of mental health of the elderly population of Russia on the basis of individual data," Population and Economics, ARPHA Platform, vol. 3(3), pages 117-140, September.
62. Richard M. Nixon & Simon G. Thompson, 2005. "Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 14(12), pages 1217-1229, December.
63. Hla-Hla Thein & Yao Qiao & Ahmad Zaheen & Nathaniel Jembere & Gonzalo Sapisochin & Kelvin K W Chan & Eric M Yoshida & Craig C Earle, 2017. "Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-20, October.
64. F. J. Vázquez‐Polo & M. A. Negrín Hernández & B. González López‐Valcárcel, 2005. "Using covariates to reduce uncertainty in the economic evaluation of clinical trial data," Health Economics, John Wiley & Sons, Ltd., vol. 14(6), pages 545-557, June.
65. Todd H. Wagner & Jean Yoon & Josephine C. Jacobs & Angela So & Amy M. Kilbourne & Wei Yu & David E. Goodrich, 2020. "Estimating Costs of an Implementation Intervention," Medical Decision Making, , vol. 40(8), pages 959-967, November.
66. Wanrudee Isaranuwatchai & Maureen Markle-Reid & Jeffrey Hoch, 2015. "Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters," PharmacoEconomics, Springer, vol. 33(10), pages 1083-1090, October.
67. David J. Vanness & John Mullahy, 2012. "Moving Beyond Mean-based Evaluation of Health Care," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 52, Edward Elgar Publishing.
68. Mike Paulden, 2020. "Calculating and Interpreting ICERs and Net Benefit," PharmacoEconomics, Springer, vol. 38(8), pages 785-807, August.
69. Luigi Siciliani & James Gaughan & Nils Gutacker & Hugh Gravelle & Martin Chalkley, 2021. "Paying for health gains," Working Papers 183cherp, Centre for Health Economics, University of York.
70. Quang Dang Nguyen & Mikhail Prokopenko, 2022. "A general framework for optimising cost-effectiveness of pandemic response under partial intervention measures," Papers 2205.08996, arXiv.org, revised Nov 2022.
71. Miguel A. Negrín & Francisco J. Vázquez-Polo & María Martel & Elías Moreno & Francisco J. Girón, 2010. "Bayesian Variable Selection in Cost-Effectiveness Analysis," IJERPH, MDPI, vol. 7(4), pages 1-20, April.
72. Peter Makai & Willemijn Looman & Eddy Adang & René Melis & Elly Stolk & Isabelle Fabbricotti, 2015. "Cost-effectiveness of integrated care in frail elderly using the ICECAP-O and EQ-5D: does choice of instrument matter?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(4), pages 437-450, May.
73. Gomes, M & Grieve, R, 2011. "Estimating the Effects of Friendship Networks on Health Behaviors of Adolescents," Health, Econometrics and Data Group (HEDG) Working Papers 11/14, HEDG, c/o Department of Economics, University of York.
74. Kim Olsen & Lone Bilde & Henrik Juhl & Niels Kjaer & Holger Mosbech & Torben Evald & Mette Rasmussen & Helle Hiladakis, 2006. "Cost-effectiveness of the Danish smoking cessation interventions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(4), pages 255-264, December.